S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 11.55 CNY -0.09% Market Closed
Market Cap: 16.9B CNY

Intrinsic Value

The intrinsic value of one Shenzhen Hepalink Pharmaceutical Group Co Ltd stock under the Base Case scenario is 10.74 CNY. Compared to the current market price of 11.55 CNY, Shenzhen Hepalink Pharmaceutical Group Co Ltd is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
10.74 CNY
Overvaluation 7%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for Shenzhen Hepalink Pharmaceutical Group Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
CN
Pharmaceuticals
Market Cap
16.9B CNY
IPO
May 6, 2010
CN
Pharmaceuticals
Market Cap
16.9B CNY
IPO
May 6, 2010
Price
ÂĄfalse
EPS
ÂĄfalse
Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Shenzhen Hepalink Pharmaceutical Group Co Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Current Assets 9.6B
Cash & Short-Term Investments 2.6B
Receivables 1.5B
Other Current Assets 5.5B
Non-Current Assets 7.7B
Long-Term Investments 1.8B
PP&E 2.6B
Intangibles 2.8B
Other Non-Current Assets 488.5m
Efficiency

Free Cash Flow Analysis
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Revenue
5.3B CNY
Cost of Revenue
-3.5B CNY
Gross Profit
1.7B CNY
Operating Expenses
-1.1B CNY
Operating Income
649m CNY
Other Expenses
-2.2m CNY
Net Income
646.7m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

Shenzhen Hepalink Pharmaceutical Group Co Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

45/100
Profitability
Score

Shenzhen Hepalink Pharmaceutical Group Co Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Shenzhen Hepalink Pharmaceutical Group Co Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Average Altman Z-Score
67/100
Solvency
Score

Shenzhen Hepalink Pharmaceutical Group Co Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Wall Street analysts forecast Shenzhen Hepalink Pharmaceutical Group Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shenzhen Hepalink Pharmaceutical Group Co Ltd is 7.55 CNY with a low forecast of 7.47 CNY and a high forecast of 7.77 CNY.

Lowest
Price Target
7.47 CNY
35% Downside
Average
Price Target
7.55 CNY
35% Downside
Highest
Price Target
7.77 CNY
33% Downside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Shenzhen Hepalink Pharmaceutical Group Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one Shenzhen Hepalink Pharmaceutical Group Co Ltd stock?

The intrinsic value of one Shenzhen Hepalink Pharmaceutical Group Co Ltd stock under the Base Case scenario is 10.74 CNY.

Is Shenzhen Hepalink Pharmaceutical Group Co Ltd stock undervalued or overvalued?

Compared to the current market price of 11.55 CNY, Shenzhen Hepalink Pharmaceutical Group Co Ltd is Overvalued by 7%.

Back to Top